Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC
Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC
Retrospective Data Highlight FRα and B7-H4 As Potential ADC Targets in Endometrial Cancer
ADC Development in Ovarian Cancer: What's Next for FRa and Beyond?